Mar 18, 2024 7:30 am EDT Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
Mar 5, 2024 7:30 am EST Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2024 4:05 pm EST Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2024 7:30 am EST Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
Dec 15, 2023 7:30 am EST Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 27, 2023 7:30 am EST Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
Nov 13, 2023 7:30 am EST Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
Nov 1, 2023 7:30 am EDT Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 26, 2023 7:30 am EDT Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
